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We present evidence of a link between interferonβ-1b (IFN-β) and G-protein signaling by demonstrating that IFN-β can induce
the expression of the negative regulator of G-protein signaling 1 (RGS1). RGS1 reduces G-protein activation and immune cell
migration by interacting with heterotrimeric G-proteins and enhancing their intrinsic GTPase activity. In this study, IFN-β
treatment resulted in the induction of RGS1 in peripheral blood mononuclear cells (PBMCs), monocytes, T cells, and B cells.
Induction of RGS1 by IFN-β was concentration dependent and observed at both the RNA and protein level. Other members of
the RGS family were not induced by IFN-β, and induction of RGS1 required the activation of the IFN receptor. In addition, RGS1
inductionwasobservedinPBMCsobtainedfromIFN-β-treated multiplesclerosispatientssuggestingapossible,asyetunexplored,
involvement of G-protein regulation in disease treatment. The upregulation of RGS1 by IFN-β has not been previously reported.
1.Introduction
A cornerstone of the inﬂammatory response is the highly
coordinated interplay of inﬂammatory regulators and im-
mune cell migration to sites of injury or infection [1–3].
Immune cells act in concert to mitigate adverse responses
resulting from exposure to toxins, bacteria, viruses, or
various pathogens [4]. Regulation of innate and adaptive
immune responses is a tightly controlled process involving a
plethora ofdiﬀerentcell typesthat interact with and respond
to changing levels of immune mediators. Migration and
accumulation of immune cells at sites of injury or infection
eventually result in the resolution of inﬂammation and
repairofdamaged tissue. However,dysregulation ofimmune
surveillanceandactivation ofimmune responses towardself-
antigens can lead to adverse eﬀects including autoimmune
diseases such as rheumatoid arthritis [5], inﬂammatory
bowel disease [6], and relapsing-remitting multiple sclerosis
(MS) [7].
Cytokines and chemokines are members of two diﬀerent
families of immune mediators that each play an indis-
pensable role in the control and regulation of an immune
response. They diﬀer based on their chromosome location,
cell speciﬁcity, protein structure and function, cell surface
receptor, and cellular signaling pathways. The immune
system makes use of these immune mediators to coordinate
and eﬃciently direct immune responses [8, 9].
Interferons (IFNs) are part of the cytokine family of
p r o t e i n sa n da r ec o m p r i s e do ft w od i ﬀerent groups: type I
(IFN-α,- β)a n dt y p eI I( I F N - γ)[ 9]. Type I and type II
IFNs diﬀer in structure, cell surface receptor, and, to some
extent, cellular signaling. Type II IFNs have been associated
with proinﬂammatory eﬀects in contrast to type I IFNs
which appear anti-inﬂammatory [9]. IFN-α and IFN-β are
located on diﬀerent chromosomes and exhibit a high degree
of homology at both the amino acid and nucleotide levels.
Type I IFNs bind to the same heterodimeric receptor
although receptor assembly and signaling events can diﬀer2 International Journal of Cell Biology
[10, 11]. Activation of the IFN receptor leads to a cascade
of intracellular signaling events involving the JAK-STAT
signaling pathway [12]. Activation of the IFN-receptor has
been demonstrated to result in the diﬀerential induction of
genes that protect against viral infection, regulate immune
cell activity, control cell growth, and reduce oxidative stress
[9, 12, 13]. IFNs are an accepted treatment for hepatitis B,
hairy cell leukemia, and malignant melanoma. In addition,
Betaseron (IFNβ-1b; Bayer HealthCare), a type I interferon,
provided the ﬁrst approved treatment for MS [14].
Chemokines are potent immune modulators that act
through a speciﬁc interaction with G-protein coupled recep-
tors (GPCR). Chemokine binding to GPCRs results in
important biologic eﬀects [15, 16]. Like IFNs, chemokines
and their receptors play a direct role in the regulation of
immune responses and are proven drug targets. As much
as 2% of the entire human genome encodes genes related
to GPCR functions, and close to 50% of all current drugs
are modulators of GPCR activity [17, 18]. One important
aspect of chemokines and their receptors is that they play
a central role in the regulation of immune cell migration
to sites of inﬂammation. Chemokine-dependent activation
of GPCRs causes the activation of heterotrimeric G-protein
subunits, leading to regulation of enzymes and ion channels
thatresultsinenhancedcellmigrationandadhesion[18–21].
A recently discovered protein family of negative regulators
of G-protein signaling (RGS) controls, in part, the extent
of G-protein subunit activation. RGS proteins terminate G-
protein signaling by accelerating GTP hydrolysis of activated
G-protein subunits [20, 21]. Upregulation of certain RGS
proteins has been shown to decrease immune cell migration
and reduce chemokine-dependent calcium ﬂux, an estab-
lishedmeasurement ofGPCRsignaling. RGSactivity appears
to be tightly controlled and highly dependent on tissue
distribution and expression.
Although the coordinated response of cytokines and
chemokines is known to be important, studies focused on
identifying mechanisms by which these two families of
immune modulators can work together to elicit an appropri-
ate immune response are limited. In this paper, we describe
for the ﬁrst time the induction of a negative regulator of G-
protein signaling 1 (RGS1) by IFN-β, suggestive of a func-
tional link between IFN and chemokine signaling.
2.Materialsand Methods
2.1. RGS1 Expression in Human PBMCs and Immune
Cell Subpopulations. Peripheral blood mononuclear cells
(PBMCs) were obtained from healthy individuals and
veriﬁed to be free of viral infection (All Cells LLC, Berkeley,
CA). RNA was isolated using Qiagen RNeasy as previously
described [13]. PBMCs (1 × 106 cells/mL) were cultured
(37◦C, 5.0% carbon dioxide (CO2)) and grown in Eagle’s
Minimum Essential Medium supplemented with 10%
v/v heat-inactivated fetal bovine serum and 2.0mM L-
glutamine. Antibiotics were not included in the cell culture
media. Cellswere incubated with orwithout IFN-β-1b (1000
International Units (IU)/mL, 1 × 107 cells), IFN-γ (R&D
Systems, Minneapolis, MN; 1000IU/mL, 1 × 107 cells) or
phorbol myristate acetate (PMA) (Roche Diagnostics,
Indianapolis, IN; 2.0ng/mL, 1×107 cells) for the times indi-
cated. IFN-β-1b concentrations used for cell stimulation in
culture media were below the pharmacological dose. Cells
were collected, washed twice in cold phosphate-buﬀered
saline (PBS), and RNA was isolated. To determine the
speciﬁcity of induction of RGS1 by IFN-β,P B M C sw e r e
stimulatedwithorwithoutIFN-β(1000IU/mL,1×107 cells)
for either 4 or 18 hours. RNA isolated at each time point
was analyzed by reverse transcription polymerase chain
reaction (RT-PCR; TaqMan) using speciﬁc RGS primer
sets (RGS1, Hs00175260 m1; RGS2, Hs00263639 m1;
RGS5, Hs00186212 m1; RGS7, Hs00243156 m1; RGS12,
Hs01017940 m1; RGS14, Hs00197761 m1) (Applied Bio-
systems, Foster City, CA).
Primary cells including B cells, monocytes, and T cells
were isolated by negative selection using MACS cell sepa-
ration (Miltenyi Biotec Inc., Germany) [22]. Purity of each
cell population was determined to be greater that 90%
by measurement of cell-type-speciﬁc surface markers using
ﬂuorescent-activated cell sorting (FACS) (data not shown).
Isolated cell populations (1 × 106 cells/mL) were incubated
with or without IFN-β (1000IU/mL) for 4 hours. After
stimulation, cells were washed in cold PBS, RNA isolated,
and RGS1 expression determined by TaqMan.
2.2. IFN Receptor-Dependent Induction of RGS1. The con-
centration of antisera needed to neutralize the IFN recep-
tor was determined using a previously characterized IFN-
dependent reporter assay [10]. Generation of a rabbit
polyclonal antisera recognizing the ectodomain of the IFN
receptor (IFNAR2c) has been previously described [11].
A stable cell line (HT1080LUC) containing an IFN reporter
was preincubated with increasing concentrations of either
preimmune or IFNAR2c-neutralizing antisera for 1 hour at
room temperature. Cells were then stimulated, with or with-
out IFN-β, for 4 hours, and reporter activity was measured
after cell lysis using a luciferase substrate (Luciferase Assay
System, Promega, Madison, WI). The amount of IFNAR2c
antisera needed to inhibit activation of the IFN-receptor was
determined relative to preimmune sera.
PBMCs (1 × 106 cell/mL) were incubated for 1 hour at
room temparature in cell-culture media containing preim-
mune sera or IFNAR2c antisera at a concentration able
to neutralize IFN-receptor activity by >95%. Cells were
stimulated with or without IFN-β (1000IU/mL) for 4 hours
followed by cell lysis and RNA isolation as previously
described. IFN-β-dependent expression of RGS1 in PBMCs
treated with preimmune sera, IFNAR2c-neutralizing sera or
control (unstimulated) samples was determined by TaqMan
as previously described.
2.3. Patients. MS patients were diagnosed with deﬁnite MS
according to the McDonald criteria and recruited for this
study as previously described [13, 23]. Patients had an
Expanded Disability Status Scale score of 2.5 ± 1.2; and all
patientsexhibitedcharacteristic magneticresonance imagingInternational Journal of Cell Biology 3
(MRI) lesions and two or more episodes of clinically evident
relapsesand remissions. Patients were continually monitored
during the course of the study and were free of exacerbations
for at least 3 months before and after blood collection. Study
approvaland written consentinformation were acquiredand
documentedasdescribedpreviously[13].Thepatientcohort
used in this study was held na¨ ıve to immunosuppressants or
corticosteroids treatment for 1 year prior to, and during, the
study.
MS patients were under treatment with Betaseron (IFN-
β) following an established clinical protocol for an average
of 1.8 ± 0.8 years before beginning the study. Prior to the
ﬁrst sample draw, therapy was discontinued for 64 hours.
After 64 hours a baseline sample (t = 0) was drawn, then
as t a n d a r dd o s eo fI F N- β (8 million IU, speciﬁc activity 2.3×
107 IU/mg) was self-administered subcutaneously under
physiciansupervision, and heparinized bloodsamplesdrawn
at4,18,and42hourspost-IFN-βadministration. PBMCand
RNA isolation was performed as previously described [13].
2.4.GeneChipandComputationalAnalysis. PBMCswereiso-
lated using Ficoll-Paque Plus (Amersham Biosciences, NJ),
andpuriﬁedRNAcharacterized usinganAgilent2100bioan-
alyzer (Agilent Instruments, Inc., Foster City, CA) [13]. RNA
was proﬁled using Aﬀymetrix oligonucleotide microarrays
(Aﬀymetrix GeneChip HG-U133A; Aﬀymetrix Inc., Santa
Clara, CA). Gene expression values were determined using
Bioconductor’s implementation of the Robust Multichip
Average (RMA) algorithm with default options [13, 24, 25].
Gene expression resulting from Aﬀymetrix probe-set mea-
surements are presented as RMA computations performed
with quantile normalization, including standardization and
background adjustment [13, 25]. GeneChip probe sets are
classiﬁed as 25-mer oligonucleotide sequences (n ∼ 11) that
hybridize to the corresponding nucleotide sequence present
in a given gene. Gene expression analysis was also performed
with the Statistical Analysis and Critical Rationalization
of Expression Data (SACRED) software analysis package
developed at Berlex Biosciences, Inc. (Richmond, CA).
2.5. Conﬁrmation of RGS1 Expression in MS Patients. Gen-
eral methods for performing quantitative RT-PCR (qRT-
PCR) have been previously described [13]. Brieﬂy, expres-
sion of RGS1 was measured using RGS1-speciﬁc primer
sets (Hs00175260 m1) (TaqMan Gene Expression Assays,
Applied Biosystems, Foster City, CA). RNA samples were
isolated using RNeasy Midi endotoxin-free Kit (Qiagen, Inc.,
Santa Clara, CA) and run in triplicate or quadruplicate for
each sample. Analyzed RNA samples were identical to those
used for gene chip analysis. PCR reactions were performed
using a 96-well Opticon II DNA Engine (BioRad, Hercules,
CA) or an ABI Prism 7900HT Sequence Detection System
(AppliedBiosystems, Foster City, CA,). Results are presented
as linearized C(t) values normalized to glyceraldehyde-3-
phosphate dehydrogenase (GAPDH).
2.6. Immunoprecipitation and Immunoblotting of RGS1.
RGS1 polyclonal antisera used for immunoprecipation was
generated against the 36 N-terminal amino acids of RGS1
(Harlan Laboratories, San Francisco, CA). The amino
acid sequence MFFSANPKELKGTTHSLLDDKMQKRRRP-
KTFGMDMKA was coupled to KLH and used to produce
RGS1 antisera in rabbits. The immunizing RGS1 peptide
sequence was used as an input sequence to query numerous
databases using the NCBIBasic Local Alignment Search Tool
(BLAST) for detecting overlapping sequence alignments.
Using this approach, the immunizing peptide sequence was
s h o w nt ob es p e c i ﬁ cf o rR G S 1o rR G S 1i s o f o r m sw i t ho n l y
a minor overlap with a predicted sequence for a G-protein
3-like molecule in Oryctolagus cuniculus (European rabbit).
RGS1 antisera was ﬁrst analyzed by ELISA to demonstrate
immune reactivity against the immunizing peptide coupled
tobovine serumalbumin. EvaluationofRGS1antiserum was
further appraised by immunoblotting using puriﬁed RGS1
containing a 6xhistidine TAG at the C-terminus [26]. 6xHis
RGS1 (5μg/200μLs a m p l eb u ﬀer) was subjected to SDS-
PAGE using a large single well comb. Following SDS-PAGE,
proteins were transferred to a polyvinylidene diﬂuoride
membrane (PVDF) (Pro-Blot, Appled Biosystems, Inc.) and
incubated in blocking buﬀer (20mM Tris-HCL (pH 7.3),
150mM NaCl containing 0.1% Tween 20) overnight at room
temperature. The resultant membrane was then cut into
individual strips, and each strip was placed in its own
well using an 8 well plastic tray. Membrane strips were
probed with either preimmune sera, RGS1 antisera, or with
a speciﬁc antibody recognizing 6xHis (6xHis Tag antibody-
HRP, Ab1187) (Abcam,Cambridge, MA). Strips probed with
the 6xHisTag antibody-HRP (1:1000 dilution) or RGS1
antisera (1:1000 dilution) or preimmune sera (1:1000
dilution) were incubated for two hours at room temperature
and washed. After washing the membrane strips in blocking
buﬀer, the strips incubated with RGS1 or preimmune
antisera were further incubatedwith a secondantibody (goat
anti-rabbit IgG-HRP; 1:2000 dilution)(Abcam, Cambridge,
MA) for 1 hour at room temperature followed by washing
in blocking buﬀer. All membrane strips were arranged
next to each other on a plastic sheet, and RGS1 (or
6xHisTagged RGS1) was detected using a chemiluminescent
detectionmethod (Supersignal WestPicoChemiluminescent
Kit, Pierce/Thermo Scientiﬁc, Rockford, IL).
For immunoprecipation of RGS1, PBMCs were in-
cubated with or without IFN-β (1000IU/mL), IFN-γ
(1000IU/mL), or PMA (2ng/mL) for 20 hours. An equal
number of cells (2 × 108) were collected by centrifugation
(2000×g, 10 minutes), washed twice in cold PBS, and
lysed in solubilization buﬀer (20mM Tris-HCl (pH 8.0)
buﬀer containing 150mM sodium chloride (NaCl), 1.0%
Nonidet P-40 (v/v), and 2mM EDTA) at 4◦C. Insolu-
ble material was removed by centrifugation (10 minutes,
10000×g, 4◦C) and RGS1 antiserum (1:500) (described
above) or preimmune (PI) (1:500) sera added to each
lysate. Lysates were incubated overnight at 4◦C, mixed with
Protein-G agarose (Boehringer Ingelheim, Inc.), incubated
for 1 hour, washed in blocking buﬀer, and bound material
(immunoprecipate) removed by incubation with SDS-PAGE
sample buﬀer. Protein-G agarose beads were removed by
centrifugation and the remaining supernatant resolved by4 International Journal of Cell Biology
sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE; 10%-20% Tris-Glycine, Invitrogen, Inc.) [11].
After electrophoresis, the resolved protein was transferred
to a PVDF membrane and incubated overnight at room
temperature in blocking buﬀer.
The membrane was then incubated with a speciﬁc chick-
en RGS1 antisera purchased from ProSci Inc, CA (1:2000
dilution) for two hours at room temperature, washed in
blockingbuﬀer,and incubatedwith a horseradish peroxidase
(HRP)-conjugated second antibody (anti-chicken IgY-HRP;
1:1000 dilution, ProSci Inc, CA). Immunoprecipated RGS1
was detected using a chemiluminescent detection method
as previously described. Protein load was calibrated to cell
number and protein concentration. After transfer to PVDF,
transferred protein was also viewed using the reversible
protein stain Ponceau S (Thermo Scientiﬁc, Rockford, IL).
2.7. Measurement of Chemokine Receptor Expression and
Apoptosis Using FACS. Ah u m a nm o n o c y t i cc e l ll i n e( T H P -
1) in active growth phase was incubated with or without
IFN-β (1000IU/mL) for 20 hours. Cells (1 × 107/mL) were
collected, washed in cold PBS, and incubated on ice for 1
hour with a formyl peptide receptor (FPR)-phycoerythrin
or CXCR4-phycoerythrin-conjugated antibody (FPR-PE or
CXCR4-PE) (Abcam, Inc. Cambridge, MA). Apoptosis was
determined by measuring the extent of expression of the
apoptosis marker annexin-PE relative to the viable cell
marker 7-amino-actinomycin D (7-AAD). FACS was per-
formed using a Beckman-Coulter Cytomic FC 500 MPL and
CMP data analysis software (Beckman-Coulter, Fullerton,
CA).
2.8. Chemotaxis Assay. Calcein AM-labeled (Molecular
Probes, Carlsbad, CA) primary monocytes and THP-1 cells
were assessed for their ability to migrate using 5-μmp o r e
size Multiscreen MIC ﬁlter plates (Millipore, Temecula, CA).
One hundred ﬁfty microliters of migration buﬀer (HBSS
plus Ca2+/Mg2+,0 . 1 %B S A )o rb u ﬀer plus SDF1α,M C P 1 ,
or MCP2 (R&D Systems, CA) was placed in the bottom
chamber. One hundred thousand IFN-β or mock-treated
cells in migration buﬀer (100μL) were gently overlaid on
t h et o pc h a m b e r .T h ec u l t u r ep l a t e sw e r ei n c u b a t e da t3 7 ◦C,
5% CO2 for 2–4 hours, and cells migrating to the bottom
chamber were quantiﬁed on a Flexstation II calibrated
to measure endpoint ﬂuorescence (488nm excitation and
538nm emission). Results are shown as percentage of
migration relative to the original number of cells applied.
2.9. Statistics. The mean values ± standard deviations (SD)
were determined for each given experiment. Statistical tests
comparingdiﬀerencesbetweengroupswereperformed using
the Student’s t-test. A P-value of <.05 was considered to be
signiﬁcant.
3.Results
3.1. Speciﬁcity of RGS1 Induction by IFN-β. RGS1 is a
memberofalargefamilyofregulatorsofG-proteinsignaling,
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Figure 1: RGS1 expression and cell-type speciﬁcity. PBMCs were
stimulated with IFN-β (1000IU/mL) for 4 hours (Figure 1(a)).
RNA was isolated, and expression of diﬀerent RGS family members
was determined by RT-PCR as described in Section 2.R e s u l t sa r e
presented as linearized C(t)v a l u e s( n = 3, ±SD) normalized to
GAPDH. For comparison, samples having background expression
were calibrated to 1.0 (black columns). RGS1 was clearly the most
predominant RGS family member induced by IFN-β after 4 hours
(white columns). Each RGS family member tested is shown on the
x-axis. Figure 1(b) shows the IFN-β-dependent expression of RGS1
in three diﬀerent primary cell populations (B cells, monocytes, T
cells). Data are presented as nonlinearized C(t)v a l u e sn o r m a l i z e d
to GAPDH (mean ± SD, n = 3). ∗P<. 05,∗∗P<. 01.
the R4 RGS proteins [27]. RGS proteins are expressed in
an u m b e ro fd i ﬀerent cell types. RGS1 is known to be
expressed in immune cells, and overexpression in B-cells
attenuates chemokine signaling [28]. In this study, the
speciﬁc induction of RGS1 by IFN-β was ﬁrst observed
in PBMCs (Figure 1). IFN-β was shown to preferentially
induce the expression of RGS1 over that of other RGS
family members including RGS2, RGS5, RGS7, RGS12,
and RGS14 (Figure 1(a)). IFN-β-dependent induction of
RGS1 was next determined in three puriﬁed immune cell
populations isolated to homogeneity (greater than 90%)
using negative selection [22]. Induction of RGS1 by IFN-
β was shown to occur in B cells, monocytes, and T cells
(Figure1(b)).Althoughall threecelltypeswere responsive to
IFN-β stimulation, RGS1 induction appeared to be strongest
in monocytes.
Speciﬁcity and kinetics of induction of RGS1 were then
evaluated. PBMCs were stimulated for 4 or 18 hours with
either IFN-β,I F N - γ, or PMA followed by determination
of RGS1 RNA expression (Figure 2). RGS1 expression was
compared to the steady-state level observed in unstimulated
cells. Results show a preferential induction of RGS1 byInternational Journal of Cell Biology 5
0
50
100
150
200
250
300
Unstimulated
4h18h 4h18h 4h18h 4h18h
+ IFN-β + IFN-γ PMA
∗
∗
∗
∗
(
2
−
Δ
C
(
t
)
,
l
o
g
1
0
s
c
a
l
e
)
N
o
r
m
a
l
i
z
e
d
l
i
n
e
a
r
C
(
t
)
v
a
l
u
e
(
n
=
3
,
±
S
D
)
Figure 2: Induction of RGS1 by IFN-β,I F N - γ,a n dP M A . PBMCs
obtained from healthy individuals were stimulated and RGS1
expression determined as described in Section 2.P B M C sw e r e
stimulated with IFN-β (1000IU/mL), IFN-γ (1000IU/mL), and
PMA (2ng/mL) for the times indicated (white column = 4h o u r s ;
gray column = 18 hours post-IFN-β stimulation). All results were
normalized to GAPDH and expressed as the mean ± SD, n = 3.
∗P<. 05.
IFN-β relative to both PMA and IFN-γ. PMA induction of
RGS1expression was also previously described in the human
monocytic cell line U937 [29].
To conﬁrm a direct role for IFN-β in the induction of
RGS1, RGS1 expression was determined in the presence of
neutralizingantibody thatblocksactivationoftheIFNrecep-
tor (Figure 3)[ 10]. The antibody concentration needed to
neutralize the IFN receptor was determined using a cell line
stably expressing an IFN-responsive reporter (HT1080LUC)
(Figure3(a))[10].HT1080LUCcellsincubatedwithneutral-
izing antibody showed astrong inhibition ofRGS1induction
after IFN-β stimulation relative to preimmune sera and
untreated cells (Figure 3(b)). These results demonstrate that
the speciﬁc induction of RGS1 by IFN-β is dependent upon
activation of the IFN receptor.
3.2. Expression of RGS1 in MS Patients. Genetic risk factors
for susceptibility to multiple sclerosis have recently been
identiﬁed [30, 31], the most prominent being HLA DRB1.
Interestingly, RGS1 was also included in one of the MS
susceptibility loci identiﬁed. In this regard, it was important
to determine if treatment of MS patients with IFN-β leads
to changes in RGS1 expression. Based on previous pharma-
cokinetic studies, MS patients were asked to stop treatment
for 64 hours to allow for a “washout” period in which
IFN-β dependent gene expression would return to baseline
levels. Patient blood was drawn just prior to administration
of IFN-β and at 4, 18, and 43 hours post-administration.
PBMCs were isolated, RNA puriﬁed and diﬀerential gene
expression analyzed. As previously demonstrated, induction
of a number of diﬀerentially expressed genes was observed
in MS patients following administration of a single dose of
IFN-β [13]. Examination of the diﬀerential gene expression
pattern using RMA and SACRED demonstrated a transient
change in diﬀerential gene expression that returned to near
preadministration levels by 42 hours [13]. Upon further
examination,weobservedtheupregulationofRNAencoding
RGS1 in all seven MS patients studied (Figure 4). This result
supportedourinitial invitro observationsanddemonstrated
the regulation of RGS1 by IFN-β in MS patients. In MS
patients, the expression of RGS1 reached a maximum level
4 hours post-administration of IFN-β a n dr e t u r n e dt on e a r
baseline by 42 hours. A similar time course of induction
of RGS1 occurred in each patient; however, patient-to-
patientvariabilityinthemagnitudeofresponse wasobserved
(Figure 4). Variability of response was not due to diﬀerences
in RNA quality or method of GeneChip analysis [13].
To validate the observed expression of RGS1 in MS patients,
we performed an RGS1-speciﬁc TaqMan assay making use
of the same RNA samples used for the initial Aﬀymetric
GeneChip analysis. Using this approach, we also observed
patient-to-patient variability in magnitude of response for
the same samples, and a maximum expression of RGS1 at 4
hours post-administration of IFN-β followed by a return to
near baseline by 42 hours (Figure 5).
3.3. IFN-β Treatment Increases RGS1 Protein Expression.
RNA expression represents the ﬁrst step in the production
of a functional protein. RNA induction generally precedes
that of protein expression although changes in RNA half-
life or stability could possibly alter the level of RNAobserved
in the cell without resulting in an increased level of protein
expression. Therefore, demonstrating that the induction of
R G S 1R N Ar e s u l t e di na ni n c r e a s ei np r o t e i ne x p r e s s i o n
was important. The ability of RGS1 antisera to recognize
RGS1 was initially determined by immunoblotting using
puriﬁed 6xHisRGS1 (Figure 6). 6xHisRGS1 was recognized
by either RGS1 antisera (Figure 6(a), lane 2) or an antibody
directed against 6Xhistidine (Figure 6(a),l a n e3 ) .P B M C s
obtained fromhealthy individualswere stimulatedwith IFN-
β,I F N - γ, or PMA for 20 hours. For normalization of protein
levels,cellnumberswere madeidenticalandanequalprotein
concentration was used for each immunoprecipitation. Cells
were lysed and RGS1 was immunoprecipitated using an
RGS1polyclonalantisera.Asshown inFigure6(b),R GS1was
strongly induced by IFN-β stimulation and clearly present
in immunoprecipitates from IFN-β- and PMA-stimulated
cells (Figure 6(b), lanes 3 and 5). RGS1 was not detected
using preimmune sera (Figure 6(b),l a n e1 )a n dR G S 1
was not appreciably detected in RGS1 immunoprecipitates
using cell lysates made from PBMCs stimulated with IFN-
γ (Figure 6(b), lane 4). However, a faint protein doublet
was observed in both unstimulated and IFN-γ stimulated
cells (Figure 6(b), lanes 2 and 4). This protein doublet likely
represents the basal level of RGS1 expression in this cell
population. The appearance of RGS1 as a protein doublet
of approximately 23kDa is consistent with its expected
molecular weight and previous observations [29]. It is
unclearwhy immunoprecipitatedRGS1appearsasadoublet.
This may occur due to an amino acid truncation, misfolding
of the protein, or the presence of protein isoforms.
3.4. Inhibition of Cell Migration by IFN-β. Previous studies
h a v ed o c u m e n t e dt h er o l eo fI F N - β in immune modulation
and expression of Th1 and Th2 cytokines [9, 12]. Less
well documented is the role of IFN-β in the regulation of6 International Journal of Cell Biology
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Figure 3: IFN-β induction of RGS1 is dependent on IFN-receptor activation. Neutralizing antisera recognizing the IFNAR2c IFN-receptor
was incubated with PBMCs at various concentrations to determine the dilution necessary to achieve greater than 95% inhibition of an
IFN-reporter assay(see Section 2). Figure 3(a): Cells (HT1080LUC) were incubated as previously described with preimmune (dark squares)
or IFNAR2c antisera (gray squares). Antibody dilution is represented on the x-axis. The extent of IFN-reporter activation is shown on the
y-axis represented as luciferase light units (LLU). IFN-reporter activity for IFN-β-stimulated HT1080LUC cells in the absence of antisera is
also shown for comparison (single gray square). Data are presented as mean (n = 4) ±SD. Figure 3(b):T a q M a na n a l y s i so fI F N - β induced
expression of RGS1 in the absence (untreated and preimmune) or presence (anti-IFNAR2c) of an IFN-receptor neutralizing antisera. RGS1
induction is expressed as linearized C(t)v a l u e sn o r m a l i z e dt oG A P D H( n = 3, mean ± SD). ∗P<. 05.
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Figure 4: Induction of RGS1 in MS patients after a single dose of
Betaseron. Seven patients with clinically deﬁned MS were selected
for study. Patients had been on treatment for an average of 1.8 ±
0.8 years and were free of exacerbations for 3 months before and
after blood collection. PBMCs were isolated and RNA expression
analyzed using GeneChip technologies described in Section 2.
Betaseron induction of RGS1 gene expression is presented as RMA
values. RGS1 (Aﬀymetrix RGS1 probe set 202988 s at) was demon-
strated to be strongly up-regulated reaching a maximum level 4
hours after administration of Betaseron. The time of blood draw
(0 hours = wash-out period before administration of Betaseron,
and 4, 18, and 42 hours post-Betaseron administration) is shown
on the x-axis. RGS1 expression (RMA non-log) is presented as a
scatterplotshowingtheresponseofeachpatientincludingthemean
expression (solid bar) for all MS patients at each time point. All
patients received a pharmacological dose of Betaseron (250μg/mL;
8MIU).
immune cell migration, a process in which chemokines,
GPCRs, and RGS proteins play a central role. While a
limited number of studies have demonstrated that IFNs
induce shedding of adhesion molecules from the cell surface
[32, 33], few studies describe a role for IFNs directly in
immune cell migration. In this regard, the upregulation of
RGS1 by IFN-β would be expected to result in a reduction
in chemokine-dependent cell migration. To determine if
such an association exists, we stimulated monocytes with
IFN-β for a time period demonstrated to suﬃciently induce
RGS1 (Figure 6). A chemokine-dependent transmigration
assay was then used to measure the degree of cell migration.
Both primary monocytes (Figure 7(a)) and the monocytic
cell line THP-1 (Figures 7(b), 7(c),a n d7(d))w e r es h o w n
to migrate across an artiﬁcial barrier when stimulated with
either SDF1α, MCP1, or MCP2. In all cases, stimulation of
monocytes or THP-1 cells with IFN-β for the time required
to elevate levels of RGS1 inhibited monocyte transmigra-
tion relative to untreated cells. Inhibition of chemokine-
dependent cell migration by IFN-β was dose dependent
and consistent with the time and concentration required
for inhibition of SDF1α-dependent calcium ﬂux (data not
shown). These results provide a direct measurement of the
eﬀect of IFN-β on cell migration but only indirectly link the
upregulation of RGS1 to regulation of cell migration.
3.5. Eﬀects of IFN-β on Chemokine Receptor Expression and
Cell Growth. It is known that IFNs can aﬀect cell surface
receptor expression and induce apoptosis. Such eﬀects couldInternational Journal of Cell Biology 7
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Figure5:ConﬁrmationofRGS1GeneChipexpressiondatausingRT-PCR. ThesameRNA obtainedfromMSpatientstreated withBetaseron
andusedforthe GeneChipstudywasusedtoindependentlyvalidatetheexpressionofRGS1usingRT-PCR. RGS1 expressionwasdetermined
using RT-PCR (TaqMan custom primer set Hs00175260 m1) at 0, 4, 18, and 42 hours post-Betaseron administration. MS 1–7 refers to MS
patients included in the initial study. Data are expressed as linearized C(t) values normalized to GAPDH. Data are presented as the mean ±
SD (n = 3).
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Figure 6: Immunoprecipation of RGS1 from human PBMCs. Puriﬁed 6xHisRGS1 was used to evaluate RGS1 immune sera (a). 6xHisRGS1
was subjected to SDS-PAGE followed by immunoblotting as described in Section 2. The resultant immunoblot was probed with either
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protein concentration. Immunoprecipated RGS1 was detected by immunoblotting using RGS1-speciﬁc antisera as described in Section 2.
Lane 1, preimmune sera IFN-β-stimulated; lane 2, RGS1 antisera (unstimulated cells); lane 3, RGS1 antisera (IFN-β-stimulated cells); lane
4,RGS1antisera(IFN-γ-stimulated cells);lane5,RGS1 antisera(PMA-stimulatedcells).The locationofRGS1 (23kDa)is indicated (RGS1).
(c)PonceauSstainingofthePVDFmembranetovisualizeeﬃciencyofproteintransferandload.Molecularweightmarkersare alsoincluded
(kDa).8 International Journal of Cell Biology
M
i
g
r
a
t
i
o
n
(
%
)
+ IFN-β
0.1 1 10 100 1000
SDF1α (nM)
0
25
50
75
Primary human monocytes
Unstimulated
(a)
M
i
g
r
a
t
i
o
n
(
%
)
+ IFN-β
0
5
10
15
20
25
0.1 1 10 100 1000
SDF1α (nM)
THP1 Cells
Unstimulated
(b)
0
1
2
3
4
5
1 10 100 1000
MCP1 (nM)
+ IFN-β
M
i
g
r
a
t
i
o
n
(
%
)
THP1 Cells
Unstimulated
(c)
1 10 100 1000
+ IFN-β
0
3
6
9
12
15
MCP2 (nM)
M
i
g
r
a
t
i
o
n
(
%
)
THP1 Cells
Unstimulated
(d)
Figure 7: Eﬀect of IFN-β on chemokine-dependent migration of monocytes. Monocyte transmigration across an artiﬁcial barrier in
response to chemokine stimulation was determined as described in Section 2. Primary monocytes incubated with IFN-β (1000IU/107 cells)
for 20 hours were stimulated with various concentrations of SDF1α (Figure 7(a)). IFN-β-stimulated (dark circles) and unstimulated (open
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of cells applied, on the y-axis.The monocyticcell line THP-1 wasincubated with IFN-β (1000IU/107 cells) for20hours and then stimulated
with increasing concentrations of either SDF1α (Figure 7(b)), MCP1 (Figure 7(c)), or MCP2 (Figure 7(d)). The concentrations of SDF1α,
MCP1, and MCP2 are shownon the x-axis (nM chemokine) and results are presented as percent of total cell migration (% migration).Data
represents mean ± SD of n = 4.
presumably give rise to indirect changes in GPCR levels and
thereby inﬂuence RGS expression. Therefore, it was impor-
tant to show that IFN-β used as described in these studies,
did not inﬂuence GPCR expression or induce apoptosis.
When using the apoptosis marker Annexin, no diﬀerence
in apoptosis was observed between untreated monocytes
(Figure 8(a)) and those treated with IFN-β (Figure 8(b)).
In terms of GPCR expression, cell-surface expression of
two GPCRs (CXCR4 and FPR) representing diﬀerent GPCR
families analyzed. Formyl peptide receptor (FPR) [34]
expression showed no diﬀerence in cell-surface expression in
the absence (Figure 8(c)) or presence (Figure 8(d))o fI F N - β
treatment.AsimilarlackofaﬀectofIFN-βonthecell-surface
expression of CXCR4 [35] was also observed (Figures 8(e)
and 8(f)).
4.Discussion
Chemokines play a major role in the traﬃcking of immune
cells to sites of inﬂammation, in and out of germinal centers
located in lymphoid tissues, and in the repair of damaged
tissue. Migration of immune cells is mediated by a com-
plex interplay between cell-surface adhesion molecules and
chemoattractant receptors and ligands [34–36]. Cytokines,
a family of immune modulators diﬀerent from chemokines,
play a central role in mediating both innate and adaptive
immunity and protection from viral infection [12, 34, 35].
Harmonizing the interplay between chemokines and cy-
tokines appears essential for the establishment of an eﬀective
and properly regulated immune response.
RGS proteins regulate chemokine-induced activation of
GPCRs by accelerating the GTPase activity associated with
theG-proteinalphasubunit.TheRGSproteinfamilyconsists
of 30 or more distinct proteins containing one or more RGS
domains. In mammalian cells, RGS proteins interact with
other molecules involved in signal transduction including
receptors, phospholipids, and scaﬀolding proteins [19–21,
27]. RGS proteins are highly regulated at the transcrip-
tional level and have unique tissue distribution. Some RGS
members like RGS2 and RGS3 have a wide distribution
of expression while others like RGS4, RGS6, RGS7, RGS8,
RGS9,RGS10,RGS11,andRGS14areonlyfoundinaspeciﬁc
organ or tissue. RGS1 appears to be highly expressed inInternational Journal of Cell Biology 9
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Figure 8: IFN-β inhibition of calcium ﬂux is not due to apoptosis or chemokine receptor down regulation. Monocytes were incubated
with IFN-β for 20 hours, and the degree of apoptosis in untreated and IFN-β treated monocytes was determined by measuring Annexin-PE
staining relative to the cell viability dye 7-AAD as described in Section 2 (a), unstimulated; (b), IFN-β-stimulated. Annexin-PE ﬂuorescence
is shown on the y-axis and 7-AAD on the x-axis. The percent (%) ﬂuorescent events (total of 10000 measurements) are shown in each
quadrant. CXCR4 and FPR expression was determined using FACS as described in Section 2. FPR expression levels are shown for control
(solidline)andunstimulated(c)andIFN-β-stimulated (d)cells.CXCR4expressionlevelsarealsoshownforunstimulated(e)andstimulated
cells (f). Cells were incubated for 20 hours with IFN-β prior to measuring CXCR4 and FPR expression levels.
lymphocytes, suggesting a role for RGS1 in immune cell
regulation. In support of this role, previous studies using
RGS knockout mice suggest a strong link between RGS1
expression and B cell migration [28].
Results described in this study identify a possible addi-
tional role for IFN-β in the regulation of immune cell func-
tion. Our ﬁndings demonstrate that IFN-β may inﬂuence
chemokine-dependentsignaling thoughinductionofa nega-
tiveregulatorofG-proteinsignaling. Regulatingimmune cell
traﬃcking to sites of inﬂammation or, as in MS, inﬂamma-
tory lesions in the central nervous system (CNS), goes hand
inhandwithimmunologicalpropertiespreviouslyassociated
with type I IFNs [9, 12, 32, 37–41]. What is surprising
is the observation that IFN-β may inﬂuence regulation of10 International Journal of Cell Biology
GTPase activity. Previous studies have described a role for
IFN-β in regulating immune cell migration by enhancing
shedding of adhesion molecules from the cell surface [33].
IFN-β regulation of RGS1 points to an additional means by
which IFNs can exert an inhibitory eﬀect on chemokine-
dependent lymphocyte migration. Such a mechanism can
help to explain the previously described involvement of IFNs
in the regulation of immune cell migration across human
brain microvascular endothelial cell monolayers [42], the
transverse of T cells through basement membranes [43], and
human lymphocyte transmigration [44].
Our observations identify IFN-β as a regulator of RGS1
expression in lymphocytes. It should be noted that IFN-β
regulation of RGS1 alone may not be suﬃcient to regulate
the full extent of ligand-dependent GPCR activation of G-
proteins. It is likely that other proteins interact with RGS1
or aﬀect the regulation of additional RGS proteins to ﬁne
tune speciﬁc activation and migration of immune cells
during inﬂammation. Recentstudieshave demonstrated that
upregulation of RGS1 reduces the migration of regulatory T-
cells (Tregs) relative to na¨ ıve T cells [45]. In this regard, G-
protein regulation by RGS1 and other RGS family members
can be highly cell-speciﬁc and involves other unidentiﬁed
factors [46, 47]. Such speciﬁcity would also suggest that RGS
control of immune cell responsiveness would be dependent
o nt h ep r e s e n c eo fag i v e nG P C R .
Translating in vitro observations made in cell culture to
in vivo responses observed directly in a disease setting
can provide valuable insights into the possible mechanism
of action of a drug. In addition, the identiﬁcation of
an RGS1 genetic risk factor susceptibility locus in MS
suggestsapossibleroleforsingle-nucleotide-polymorphism-
derived RGS1 variants in disease susceptibility. Therefore,
it is interesting to note that RGS1 is upregulated in IFN-β
treated MS patients perhaps in an eﬀort to compensate
for an abnormal RGS1. A hallmark of MS is the develop-
ment of inﬂammatory lesions in the CNS. Formation of
inﬂammatory lesions in MS patients as recognized by MRI
using gadolinium enhancement is a measurement of CNS
inﬂammation associated with MS [48]. Formation of lesions
within the CNS is thought to be mediated, in part, by the
migration of activated immune cells from the periphery
into the CNS. Once in the CNS, they interact with local
antigen-presenting cells including astrocytes and microglia
to further drive formation of inﬂammatory lesions visible
by MRI. In addition, suppression of immune responses in
MS patients has been linked to a reduction in the levels
of oxidative stress, which, when left unchecked, can lead
to neurodegeneration and axonal loss commonly observed
in MS [49, 50]. The observed in vitro upregulation of
RGS1 by IFN-β provided the opportunity to study the in
vivo regulation of RGS1 directly in MS patients treated
with IFN-β. Although only seven individual patents were
studied,all patientsshowed signiﬁcant upregulationofRGS1
expression after IFN-β administration. Studiesare underway
to conﬁrm this observation using a larger cohort of MS
patients. The upregulation of RGS1 as measured by gene
expression proﬁling in MS patients highlights the possible
importance of RGS1 for the regulation of chemokine activity
in the treatment of MS. A single study such as this is not
suﬃcientto demonstrateRGS1regulationbyIFN-β provides
a new sole mechanism of action, nor is the eﬀect likely
unique to MS. However, such a mechanism could help to
explaintheobservedinhibitoryeﬀectsofIFN-βonmigration
of activated immune cells from the periphery to sites of
inﬂammation within the CNS.
IFN-β inhibition of cell migration demonstrates a role
for IFN-β in the regulation of immune cell migration. RGS1
upregulatedbyIFN-βwouldbeexpectedtoenhanceimmune
cell migration by accelerating GTPase activity, negatively
regulating G-protein coupled receptor signaling. IFN-β was
demonstrated to inhibit monocyte migration across an
artiﬁcial barrier in response to chemokine. Inhibition of cell
migration coincided with the time required to upregulate
RGS1 in immune cells, suggesting an association between
inhibition of cell migration and expression. Unfortunately,
we were unsuccessful in identifying an siRNA able to down-
regulate RGS1 expression in these cells. Therefore, a direct
link between IFN-β induced RGS1 and cell migration will
require further studies. ARGS1 murine knockoutisavailable
and could provide an additional means to studying the role
of IFN-β in regulation of RGS1 and cell migration. IFN-β
did not appear to aﬀect GPCR receptor expression or induce
apoptosis in immune cells using conditions described in this
study. Therefore, the observed reduction in monocyte cell
migration was not due to an induction of cell death or a loss
of G-protein coupled receptors from the cell surface.
The observation that a cytokine such as IFN-β can
inﬂuence chemokine-dependent G-protein activation sug-
gests a possible mechanism for crosstalk between these
two important families of immune regulators. Studies are
underway to further understand the relationship between
IFN-β, GPCRs and RGS proteins with regard to control
of immune cell surveillance, maturation, migration, and
inﬂammation.
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